Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial

Published:2022-11-14 Issue:12 Volume:7 Page:1987-1995
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Gatechompol Sivaporn,Kittanamongkolchai Wonngarm,Ketloy Chutitorn,Prompetchara Eakchai,Thitithanyanont Arunee,Jongkaewwattana Anan,Buranapraditkun Supranee,Alameh Mohamad-Gabriel,Ubolyam Sasiwimol,Sophonphan Jiratchaya,Apornpong Tanakorn,Kerr Stephen,Kamarulzaman Adeeba,Siwamogsatham Sarawut,Kroon Eugène,Puthanakit Thanyawee,Patarakul Kanitha,Palaga Tanapat,Wijagkanalan Wassana,Carpenter Alexis,Hong Lina,Weissman Drew,Ruxrungtham Kiat^ORCID,

Funder

Chulalongkorn University

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

Link

https://www.nature.com/articles/s41564-022-01271-0.pdf

Reference17 articles.

1. Coronavirus Pandemic (COVID-19) Vaccinations (Our World in Data, 2020).

2. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).

3. Prompetchara, E. et al. Immunogenicity and protective efficacy of a sars-cov-2 mrna vaccine encoding secreted non-stabilized spike protein in mice. Preprint at bioRxiv https://doi.org/10.1101/2022.09.07.506878 (2022).